Log ind
Jan van de Winkel4.jpg
Foto: Stine Bidstrup

”A drug like Darzalex only comes along once every 20 years”

Top picks in English:

Genmab’s CEO is ecstatic over the biotech's “shining star”, bone marrow cancer drug Darzalex. He doubts he will see anything like it in his time in the company, but is working intently on finding a new cash cow.


BY LOUISE WENDT JENSEN
Offentliggjort 28.02.17 kl. 16:22

Log ind for at læse artikler

Velkommen til MedWatch. En del af vores indhold er eksklusivt og forbeholdt vores brugere.

Prøv os gratis i 14 dage

Få fuld adgang til vores kvalitetsjournalistik med et gratis prøveabonnement.

Sign up for MedWatch newsletter
Mest læste Top picks in English

Here is what Danish drug companies pay their workers

Løn Top picks in English:

The average monthly salary in the private pharmaceutical industry in Denmark is DKK 57,109. Make the jump to find out which company pays the highest wages and learn how much the rest of the industry pays as well.

Chemometec’s new growth engine could attract buyers

Top picks in English:

Chemometec is banking big on a new analysis device, scheduled for a broad launch during 2017. If the product lives up to the company’s own expectations, it could have wide-reaching consequences for the medtech company, one analyst believes.

Danish hearing aid giants in global showdown

Top picks in English:

The world’s largest hearing device dealer, Amplifon, expresses concern over the entry into the retail market of manufacturers such as William Demant. GN Resound, on the other hand, receives praise and is expected to form even closer ties to its Italian collaborator.

Action Pharma founder is preparing another sale

Top picks in English:

Søren Nielsen, who was one of the founders of Action Pharma, has quietly been building a new company that he expects to offload to Big Pharma by the close of 2015. There are, however, still a couple of challenges on the way.

Novo among the 100 most valuable companies in the world

Top picks in English:

Novo Nordisk has made it onto the list of the world’s 100 most valuable companies for the first time, but the Danish company is still trailing the biggest players in the pharmaceutical industry.

ALK-director: Important strategic approval

Top picks in English:

With the expansion of the indication for their house dust mite pill, which now also covers the age range from 12-17 years, ALK gets access to a strategically important market segment.

Forsiden lige nu

Nyt opkøb i medicobranchen til trecifret mia-beløb

COLOURBOX14112799.jpg Medico & Rehab:

En amerikansk Coloplast-rival er på vej til at blive solgt for 24 mia. dollars – næsten 167 mia. kr. Handlen skal godkendes af myndighederne før den kan gå endeligt igennem.

Her vil Sanofi udfordre sine diabetesrivaler

Medicinal & Biotek:

Den franske medicinalkoncern Sanofi har kandidater på vej i to af de største nye lægemiddelklasser på diabetesområdet, og selskabets danske diabetesforskningschef mener, at man kan differentiere sig fra konkurrenter som blandt andre Novo Nordisk på vigtige parametre.

Markedet er ligeglad med AbbVies flotte hep c-resultater

Medicinal & Biotek:

AbbVie har netop fremlagt nye, stærke fase 3-resultater på deres lægemiddelkandidat mod hepatitis c, men hep c-markedet er så benhårdt, at analytikerne ikke giver meget for AbbVie chancer.

Laboratorieleverandør vokser på nordisk salg

Medico & Rehab:

Den danske laboratorieleverandør Ramcon glæder sig over fremgang i både bruttofortjeneste og årsresultat. Især har væksten været markant i Norden uden for Danmark.

MW-indeks: Investordarling vender kursen med flotte salgstal

Medicinal & Biotek:

En investordarling, som ellers har været prøvet på aktiekursen i de seneste uger, har med flotte nye salgstal vendt skuden, mens andre gode nyheder ikke finder nåde for investorernes blik.

Dansk biotekselskab leverer gyldent afkast i Sverige

Medicinal & Biotek:

Med en fantastisk kursudvikling siden sin børnotering i Sverige for små to år siden, går det rigtigt godt for danske Oncology Venture, som arbejder med at udvikle personlig kræftmedicin.

ANNONCE
ANNONCE


ANNONCE